The inhibition of PD-1 and PD-L1 pathways has emerged as one of the most effective therapeutic strategies in various cancers [5] and several antibodies targeting PD-1 or its ligand, PD-L1 have been approved to treat various solid and hematologic malignancies [6–11]. This evidence concerns the gene CD274 and cancer.